Published research underpinning the Constructive Bio platform — from fundamental genetic code expansion to scalable biomanufacturing.
May 22, 2026
Syn57 dramatically expands the ‘codon space’ available for non-canonical amino acid incorporation, from three freed codons in Syn61 to seven…
June 1, 2025
Viral contamination is a major cost and quality risk in biomanufacturing. Phage infection can wipe out an entire production run,…
December 1, 2024
Speed matters in drug development. Automating tRNA generation means Constructive Bio can rapidly create the molecular machinery needed to incorporate…
January 25, 2024
Directed evolution is how drug developers optimise protein therapeutics for potency, stability, and manufacturability. This orthogonal replication system lets Constructive…
January 1, 2024
Peptide drugs are rapidly degraded in the body, requiring frequent injection. Non-standard backbone chemistries make peptides resistant to the enzymes…
July 1, 2023
Writing genomes at megabase scale is the core technical capability that makes Constructive Bio’s platform possible. This paper demonstrates the…
June 1, 2023
Pharmaceutical companies developing ncAA-containing peptide therapeutics need to know: how many different non-canonical amino acids can be incorporated into one…
October 1, 2022
Regulators and pharmaceutical partners need assurance that genetically modified production organisms cannot spread engineered genes into the environment. Bidirectional genetic…
October 1, 2022
This is the most direct scientific proof-of-concept for Constructive Bio’s commercial proposition. It demonstrates that peptide macrocycles — the structural…
September 1, 2021
Moving from single ncAA incorporation to four distinct ncAAs in one protein represents a step-change in what biological manufacturing can…
June 4, 2021
This paper demonstrates two of Constructive Bio’s core platform advantages in a single organism. Virus resistance means safer, more reliable…
April 1, 2021
REXER and GENESIS are the ‘how’ behind Constructive Bio’s genome synthesis capability. They enable the precise, large-scale rewriting of bacterial…
December 14, 2020
A high-level field-defining review that helps frame why genetic code reprogramming matters scientifically and commercially.
May 29, 2020
One of the key enabling steps toward multiplexed ncAA incorporation and the programmable synthesis of chemically richer biomolecules.
April 1, 2020
The range of therapeutic applications depends on how many different ncAAs can be incorporated. This rapid discovery platform means Constructive…
August 30, 2019
Adds a powerful structural genome-engineering capability that complements sequence rewriting and whole-genome synthesis.
May 15, 2019
Syn61 is the origin of Constructive Bio’s programmable biology platform. By proving that an organism can survive with a compressed…
May 1, 2019
Drug discovery requires screening large libraries to find peptide candidates. This work enables those libraries to include non-canonical amino acids…
October 1, 2016
Systematic Synonymous Codon Compression Demonstrates Genome-Scale Codon Removal Is Viable in E. coli
This was the proof-of-principle that codon compression works at genome scale. Before this paper, it was unclear whether removing synonymous…
